• home
  • articles
  • authors
  • Reviewers
  • About the Journal
  • About the Journal
  • About the Journal
  • About the Journal
  • e-Submission

Indexed/Covered by

J Vet Sci 2018; 19(3): 393-405  https://doi.org/10.4142/jvs.2018.19.3.393
Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity
Rachel F. Madera1, Lihua Wang1, Wenjie Gong2, Yulia Burakova1, Sterling Buist1, Jerome Nietfeld3, Jamie Henningson3, Ada G. Cino-Ozuna3, Changchun Tu2, Jishu Shi1,*
Departments of 1Anatomy and Physiology, and 3Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
2Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun 130062, China
Correspondence to: Tel: +1-785-532-5666; Fax: +1-785-532-4557; E-mail: jshi@ksu.edu
Received: November 23, 2017; Revised: February 6, 2018; Accepted: February 10, 2018; Published online: May 31, 2018.
Abstract
Highly contagious classical swine fever (CSF) remains a major trade and health problem in the pig industry, resulting in large economic losses worldwide. In CSF-endemic countries, attenuated CSF virus (CSFV) vaccines have been routinely used to control the disease. However, eradication of CSFV in a geographical area would require permanent reduction to zero presence of the virus. It is therefore of paramount importance to develop a safe, potent, and non-infectious CSF vaccine. We have previously reported on a cost-effective CSF E2 subunit vaccine, KNB-E2, which can protect against CSF symptoms in a single dose containing 75 µg of recombinant CSFV glycoprotein E2. In this study, we report on a series of animal studies undertaken to elucidate further the efficacy of KNB-E2. We found that pigs vaccinated with a single KNB-E2 dose containing 25 µg of recombinant CSFV glycoprotein E2 were protected from clinical symptoms of CSF. In addition, KNB-E2-mediated reduction of CSF symptoms was observed at two weeks post-vaccination and the vaccinated pigs continued to exhibit reduced CSF clinical signs when virus challenged at two months and four months post-vaccination. These results suggest that KNB-E2 effectively reduces CSF clinical signs, indicating the potential of this vaccine for safely minimizing CSF-related losses.
Keywords: adjuvants, classical swine virus, subunit, vaccines


© 2018 The Korean Society of Veterinary Science.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.